Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia

European Journal of Haematology

Volumn 74, Issue 1, 2005, Pages 35-39

  Ho, Ching Liang ^a   Arora, Brijesh ^b   Hoyer, James D ^b   Wellik, Linda E ^b   Mesa, Ruben A ^b   Tefferi, Ayalew ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Myelofibrosis with myeloid metaplasia; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOLID TUMOR; STAINING; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12444281837     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00355.x     Document Type: Article

References (41)

1. HANAHAN D, WEINBERG RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. FOX SB. Tumour angiogenesis and prognosis. Histopathology 1997;30:294-301.
3. RAJKUMAR SV, LEONG T, ROCHE PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-3116.
4. AGUAYO A, KANTARJIAN H, MANSHOURI T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
5. RAJKUMAR SV, MESA RA, FONSECA R et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research 2002;8:2210-2216.
6. MESA RA, HANSON CA, RAJKUMAR SV, SCHROEDER G, TEFFERI A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
7. BERGERS G, BENJAMIN LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
8. VEIKKOLA T. ALITALO K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-220.
9. KERBEL RS, VILORIA-PETIT A, OKADA F, RAK J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998;4:286-295.
10. LINDERHOLM B, TAVELIN B, GRANKVIST K, HENRIKSSON R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998;16:3121-3128.
11. TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
12. YUAN A, YU CJ, CHEN WJ et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000;89:475-483.
13. MAEDA K, CHUNG YS, OGAWA Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863.
14. SMITH BD, SMITH GL, CARTER D, SASAKI CT, HAFFTY BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000;18:2046-2052.
15. PARADIS V, LAGHA NB, ZEIMOURA L et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351-356.
16. AGUAYO A, ESTEY E, KANTARJIAN H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
17. VERSTOVSEK S, KANTARJIAN H, MANSHOURI T et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002;99:2265-2267.
18. AGUAYO A, O'BRIEN S, KEATING M et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000;96:768-770.
19. SALVEN P, ORPANA A, TEERENHOVI L, JOENSUU H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 2000;96:3712-3718.
20. GILES FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 2001;6 (Suppl. 5):32-39.
21. VERSTOVSEK S, ESTEY E, GILES FJ et al. Clinical relevance of vascular endothelial growth factor (VEGF) receptors 1 and 2 in a acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood 2000;96:103a.
22. DO RAIMONDO F, AZZARO MP, PALUMBO GA et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001;15:976-980.
23. MUSOLINO C, CALABRO L, BELLOMO G et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159-163.
24. BIKFALVI A, HAN ZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994;8:523-529.
25. BANKS RE, FORBES MA, KINSEY SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964.
26. CHOU JM, LI CY, TEFFERI A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res 2003;27:499-504.
27. TEFFERI A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
28. BAROSI G, AMBROSETTI A, FINELLI C et al. The Italian Consensus Conference on Diagnostic Criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999;104:730-737.
29. YOON SY, TEFFERI A, LI CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000;104:151-157.
30. THIELE J, KVASNICKA HM. Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma? Acta Haematol 2004;111:155-159.
31. REILLY JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997;11:233-242 (Review, 99 refs).
32. MARTYRE MC, ROMQUIN N, LE BOUSSE-KERDILES MC et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
33. MARTYRE MC, LE BOUSSE-KERDILES MC, ROMQUIN N et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441-448.
34. KIMURA A, KATOH O, HYODO H, KURAMOTO A, SATOW Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk Lymphoma 1995;18:237-242 (Review, 47 refs).
35. WROBEL T, MAZUR G, SUROWIAK P, WOLOWIEC D, JELEN M, KULICZKOWSKY K. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res 2003;9:170-173.
36. MESA R, KAY N, LI CY, BONE N, GRAY L, TEFFERI A. Urinary markers of angiogenesis and their correlation with intramedullary manifestations of angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2002;100:347b.
37. VACCA A, RIA R, RIBATTI D et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88:176-185.
38. HANAHAN D, FOLKMAN J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
39. KUMAR S, WITZIG TE, TIMM M et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-1165.
40. FOLKMAN J. Looking for a good endothelial address. Cancer Cell 2002;1:113-115.
41. RELF M, LEJEUNE S, SCOTT PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.